Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.

Date publication

octobre 2024

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Parigi TL, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, Biedermann L, Colombel JF, Dignass A, Fumery M, Ghosh S, Kobayashi T, Louis E, Magro F, Panaccione R, Rausch A, Reinisch W, Selinger C, Jairath V, Danese S, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39367753

Résumé

Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative colitis (UC) and Crohn's disease (CD).

Mots clés

Crohn's disease, IBD, clinical trials, deep remission, endoscopy, histologic healing, histological healing, neutrophils, pathology, ulcerative colitis

Référence

United European Gastroenterol J. 2024 10 5;: